Moussa, S., Amer, S., Nagy, N., Galala, S., Elgendi, M., El Ashiry, S. (2023). Salivary Levels of Soluble Fas in Oral Lichen Planus Patients Before and After Treatment with Topical Corticosteroids. Egyptian Dental Journal, 69(1), 439-446. doi: 10.21608/edj.2022.175893.2355
Sarah Moussa; Sherif Amer; Noha Nagy; Sara Galala; Mai Elgendi; Shahira El Ashiry. "Salivary Levels of Soluble Fas in Oral Lichen Planus Patients Before and After Treatment with Topical Corticosteroids". Egyptian Dental Journal, 69, 1, 2023, 439-446. doi: 10.21608/edj.2022.175893.2355
Moussa, S., Amer, S., Nagy, N., Galala, S., Elgendi, M., El Ashiry, S. (2023). 'Salivary Levels of Soluble Fas in Oral Lichen Planus Patients Before and After Treatment with Topical Corticosteroids', Egyptian Dental Journal, 69(1), pp. 439-446. doi: 10.21608/edj.2022.175893.2355
Moussa, S., Amer, S., Nagy, N., Galala, S., Elgendi, M., El Ashiry, S. Salivary Levels of Soluble Fas in Oral Lichen Planus Patients Before and After Treatment with Topical Corticosteroids. Egyptian Dental Journal, 2023; 69(1): 439-446. doi: 10.21608/edj.2022.175893.2355
Salivary Levels of Soluble Fas in Oral Lichen Planus Patients Before and After Treatment with Topical Corticosteroids
1Lecturer of Oral Medicine, Periodontology and Diagnosis, Faculty of Oral and Dental Medicine, Future University in Egypt
2Assistant Lecturer of Oral Medicine, Periodontology and Diagnosis, Faculty of Oral and Dental Medicine, Future University in Egypt.
3Professor of Oral Medicine, Periodontology and Diagnosis, Faculty of Oral and Dental Medicine, Future University in Egypt.
Abstract
Purpose: Oral Lichen planus (OLP) is a chronic mucocutaneous disorder. Some factors associated in induction of apoptosis in OLP include Fas/FasL pathway. The aim of this investigation was to detect the salivary levels of apoptotic related marker soluble Fas (sFas) in OLP patients. Methods: 30 individuals were divided into 2 groups: 15 patients suffering from OLP and 15 healthy individuals as controls. Clinical score for OLP lesions and pain assessment at exacerbation was collected. Saliva samples were collected twice from the OLP group at baseline and after topical corticosteroid treatment and once from control group. Results: The mean salivary levels of sFas were significantly higher in OLP group at baseline than that of control group. After treatment sFas levels, pain and clinical scores decreased significantly in OLP group when compared to baseline. Conclusion: sFas levels in saliva were higher in patients with OLP when compared to controls and decreased significantly after treatment which may emphasize its role in the pathogenesis of the disease.
Top